Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Surgical treatment of malignant pleural mesothelioma
Authors:ID Eržen, Janez (Author)
ID Vidmar, Stanko (Author)
ID Sok, Mihael (Author)
ID Debeljak, Andrej (Author)
ID Kecelj, Peter (Author)
ID Kovač, Viljem (Author)
ID Stanovnik, Marjeta (Author)
ID Rott, Tomaž (Author)
ID Kern, Izidor (Author)
Files:.pdf PDF - Presentation file, download (82,10 KB)
MD5: 4F59CCA8F92DE43AA1534CF667F108D2
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Background. The aim of the study was to identify perioperative morbidity and mortality, the category and mode of adjuvant treatment, local recurrence and survival in patients treated by extrapleural pneumonectony (EPP) for malignantpleural mesothelioma (NLPM). Methods. From 2000 to 2003, 18 patients with MPM were referred to the Department of Thoracic Surgery in Ljubljana, and17 of them were operated on. Two patients underwent explorative thoracotomy, and 15 patients were evaluated. Five female and nine male patients (aged 52-68 years) were treated by EPP and one male patient by pleurectomy. Eight patients received both adjuvant chemotherapy (ChT) and radiotherapy (RT), with cisplatin 100 mg/m2 + mitomycin C 6-10 mg/m2 gemcitabine 1000 mg/m2 and external beam radiation with 24 Gy - 58 Gy respectively, three patients received no adjuvant therapy, three patients weretreated by adjuvant ChT, two of them were given cisplatin 100 mg/m2 + mitomycin C 6-10 mg/m2, and one patient cisplatin 100 mg/m2 on the first day and gemcitabine 250 mg/rn2 in prolonged 6 hours infusion on the first and on the eighth day. One patient was treated only by adjuvant RT. Results. There were no perioperative deaths and the postoperative morbidity was 42%. Of the 15 evaluable patients, and in the median follow up of 40 months (28-64), we noticed nine (60.0%) recurrences, seven local and two abdominal. Eight (53.3%)patients died, all because of the local progress of disease. (Abstract truncated at 2000 characters)
Publication status:Published
Publication version:Version of Record
Publication date:01.01.2005
Publisher:Association of Radiology and Oncology
Year of publishing:2005
Number of pages:str. 123-131
Numbering:Letn. 39, št. 2
Source:Ljubljana
PID:20.500.12556/DiRROS-18168 New window
UDC:616.2
ISSN on article:1318-2099
COBISS.SI-ID:19765721 New window
Copyright:by Authors
Note:BSDOCID115521;
Publication date in DiRROS:14.02.2024
Views:548
Downloads:127
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Radiology and oncology
Shortened title:Radiol. oncol.
Publisher:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 New window

Secondary language

Language:Slovenian
Title:[Kirurško zdravljenje malignega plevralnega mezotelioma
Abstract:Izhodišča. Namen raziskave je bil ugotoviti operacijske zaplete, pooperacijskosmrtnost, vrsto in načine dopolnilnega zdravljenja, potek bolezniin preživetje pri bolnikih, pri katerih je bila narejena ekstraplevralna pnevmonektomija (EPP) ali plevrektomija zaradi malignega plevralnega mezotelioma (MPM). Metode. V letih od 2000 do 2003 je bilo 18 bolnikov z MPM napotenih na Klinični oddelek za torakalno kirurgijo Kliničnegacentra v Ljubljani. Operirali smo 17 bolnikov in pri dveh naredili samo eksplorativno torakotomijo, preostalih 15 pa smo operirali z namenom ozdravitve. Pri 5 ženskah in 9 moških (starih od 52 do 68 let) smo naredili EPP, pri enem pa plevrektomijo. Osem bolnikov je po operaciji dobivalo cisplatin 100 mg/m2 + mitomicin C 6-10 mg/m2 (5 bolnikov) ali gemcitabin 1000 mg/m2(3 bolniki) in imelo obsevanje hemitoraksa od 24 Gy do 58 Gy (KT+RT); 3 niso bili dodatno zdravljeni; 3 so prejeli le citostatike brez obsevanja (KT) od tega sta 2 bolnika dobila cisplatin 100 mg/m2 + mitomicin C 6-10 mg7m2, eden pa cisplatin 100 mg/m2 in gemcitabin v podaljšani infuziji (250 mg/m2 1. in 8. dan); en bolnik je bil le obsevan (54 Gy). Rezultati. V zgodnjem pooperacijskem obdobju ni nihče umrl, pooperativnih zapletov pa je bilo 42%. Vsrednjem opazovalnem obdobju 40 mesecev (28-64) smo pri 9 do 5 (60%) bolnikihugotovili ponovitev bolezni, 8 od 15 (53,3%) bolnikov je umrlo, vsi zaradi lokalne ponovitve tumorja.(Izvleček skrajšan na 2000 znakov)


Back